Table 8:

Study Characteristics of Ranibizumab Versus Bevacizumab A-VEGF RCTs for n-AMD

Study, Author, Year, Country	Study Design and Follow-Up	Sites, Patients, Trial Arms	Maintenance Follow-Up	Re-treatment Criteria
CATT, Catt Research Group, 2011, (62;64;65) United States	4-arm active groups, single-masked multicentre non-inferiority RCT 1–2 years	44 sites, 1208 Ps 1 MoLD of ranibizumab + M 1MoLD of ranibizumab + PRN 1MoLD of bevacizumab + M 1MoLD of bevacizumab + PRN	Follow-up included: monthly ophthalmologic exams; TD-OCT (PRN only), VA, and FA performed at the investigators’ discretion	1) Fluid on TD-OCT 2)) new or persistent hemorrhage 3) decreased VA (before previous) 4) dye leakage or FA showing increased lesion size
MANTRA, Krebs et al, 2013, (61) Austria	2-arm active groups double-masked multicentre non-inferiority RCT 1 year	10 sites, 321 Ps 3MoLD of ranibizumab + PRN 3MoLD of bevacizumab + PRN	Follow-up included monthly study visits with biomicroscopy, IOP, BCVA, OCT, medicine and adverse event check; FA was performed at baseline and at 12 months	1) VA decreased ≥ 5 letters with OCT or FA evidence of macular fluid 2) CRT increased ≥ 100 μm on OCT 3) new macular hemorrhage 4) new area showing CNV 5) persistent fluid on OCT(> 1 month after injection)
IVAN, Chakravarthy et al, 2012, (60) United Kingdom	4-arm active groups single-masked multicentre non-inferiority RCT 1 year	23 sites, 628 Ps 3MoLD of ranibizumab + BiM 3MoLD of ranibizumab + PRN 3MoLD of bevacizumab + BiM 3MoLD of bevacizumab + PRN	Follow-up included monthly visits with BCVA, clinical exams, OCT, and fundus photography with FA at baseline and months 12 and 24	1) On OCT any SRF, increasing IRF, or fresh blood 2) VA decrease by ≥ 10 letters 3) On FA leakage > 25% lesion circumference or expansion CNV
Subramanian et al, 2012, (63) United States	2-arm active groups double-masked RCT 1 year	1 site, 28 Ps (Veterans Affairs) 3MoLD of ranibizumab + PRN 3MoLD of bevacizumab + PRN	Follow-up included monthly visits with VA, OCT, and clinical exams	1) On OCT any qualitative increase in IRF or SRF 2) Worsening VA 3) Increased fluid or hemorrhage leading to FA

Abbreviations: BCVA, best corrected visual acuity; BiM, bimonthly; CNV; classic neovascularization; CRT, central retinal thickness; FA; fluorescein angiography; IOP, intraocular pressure; IRF, intraretinal fluid; 1MoLD, 1-month loading dose; 3MoLD, 3-month loading dose; M, monthly; OCT, optical coherence tomography; P, patient; PRN, pro re nata (as needed); SRF, subretinal fluid; RCT, randomized controlled trial; TD-OCT, time domain–optical coherence tomography; VA, visual acuity.